China Accelerates Development of Marine Biopharmaceutical Industry
China's marine biopharmaceutical industry has developed significantly, with the industry's added value reaching 99.6 billion yuan by 2025. It dominates over 80% of the global marine raw material market. The government has launched initiatives to promote innovation and the development of novel marine drugs, such as BG136, a anticancer medication derived from brown algae, currently in Phase II clinical trials. Additionally, Chinese companies have developed marine bio-products, including materials for bone filling and tissue repair membranes, which reduce costs and increase the availability of health products based on marine resources.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)